Czech Pharma Summit 2025
What they said about us
„Generic and biosimilar medicines help the health system to reduce treatment costs, and thanks to that, the treatment is accessible to more patients.”
„Generics and biosimilars represent, from the perspective of a health insurance company, a key tool for the efficient use of public health insurance funds and for maintaining the accessibility of care. They make it possible to treat more patients with the same resources while also creating room for financing modern treatment. Their role is essential to the stability of the system as well as to patients' access to therapy.”
„Generics and biosimilars are an important pillar to ensure the availability of medicines. Especially recently, the importance of having sufficient diversity in supply chains to provide an alternative product in the event of a failure has become apparent.”
Our members
